DE3783105D1 - Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten. - Google Patents

Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.

Info

Publication number
DE3783105D1
DE3783105D1 DE8787902015T DE3783105T DE3783105D1 DE 3783105 D1 DE3783105 D1 DE 3783105D1 DE 8787902015 T DE8787902015 T DE 8787902015T DE 3783105 T DE3783105 T DE 3783105T DE 3783105 D1 DE3783105 D1 DE 3783105D1
Authority
DE
Germany
Prior art keywords
chinolinylaether
tetrazole
media
sensitive diseases
treating hyper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787902015T
Other languages
English (en)
Other versions
DE3783105T2 (de
Inventor
Raymond Youssefyeh
Utpal Chakraborty
Ernest Magnien
Rohit Desai
D-Y Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/839,410 external-priority patent/US4839369A/en
Priority claimed from US06/911,028 external-priority patent/US4868193A/en
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Publication of DE3783105D1 publication Critical patent/DE3783105D1/de
Application granted granted Critical
Publication of DE3783105T2 publication Critical patent/DE3783105T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8787902015T 1986-03-13 1987-03-11 Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten. Expired - Fee Related DE3783105T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/839,410 US4839369A (en) 1985-04-16 1986-03-13 Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US06/911,028 US4868193A (en) 1986-09-24 1986-09-24 Styryl tetrazoles and anti-allergic use thereof
PCT/US1987/000560 WO1987005510A1 (en) 1986-03-13 1987-03-11 Quinolinyl ether or thioether tetrazoles as agents for the treatment of hypersensitive ailments

Publications (2)

Publication Number Publication Date
DE3783105D1 true DE3783105D1 (de) 1993-01-28
DE3783105T2 DE3783105T2 (de) 1993-04-22

Family

ID=27126105

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787902015T Expired - Fee Related DE3783105T2 (de) 1986-03-13 1987-03-11 Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.

Country Status (7)

Country Link
EP (1) EP0260305B1 (de)
JP (1) JPS63503139A (de)
AT (1) ATE83376T1 (de)
AU (1) AU612569B2 (de)
CA (1) CA1324142C (de)
DE (1) DE3783105T2 (de)
WO (1) WO1987005510A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962203A (en) * 1985-06-18 1990-10-09 Merck Frost Canada, Inc. 2-substituted quinolines useful as leukotriene antagonists
MA20977A1 (fr) * 1986-05-19 1987-12-31 Ciba Geigy Ag Plantes tolerant les herbicides contenant le gene de gluthathione S-Transferase
EP0271287A3 (de) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Chinolindicarbonsäuren und ihre Amide
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920133A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5204358A (en) * 1987-11-25 1993-04-20 Merck Frosst Canada, Inc. Hetaryl styryl quinolines as leukotriene inhibitors
US5104882A (en) * 1987-11-25 1992-04-14 Merck Frosst Canada, Inc. Diarylstrylquinoline diacids and pharmaceutical compositions thereof
IL88433A0 (en) * 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
NZ229761A (en) * 1988-07-12 1991-10-25 Ici Pharma Substituted thiazole derivatives for use as inhibitors of enzyme 5-lipoxygenase; pharmaceutical compositions and preparatory processes
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
ATE117294T1 (de) * 1989-08-11 1995-02-15 Ici Plc Chinolin-derivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel.
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
DE4129742A1 (de) * 1991-09-06 1993-03-11 Bayer Ag Heterocyclisch substituierte chinolylmethoxy-phenylacetamide
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4202985A (en) * 1978-10-25 1980-05-13 E. R. Squibb & Sons, Inc. Imidazolylethoxy derivatives of quinoline-3-methanols
DE3275295D1 (en) * 1981-11-12 1987-03-05 Fisons Plc Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines

Also Published As

Publication number Publication date
WO1987005510A1 (en) 1987-09-24
EP0260305B1 (de) 1992-12-16
AU612569B2 (en) 1991-07-18
JPS63503139A (ja) 1988-11-17
EP0260305A4 (de) 1988-07-04
CA1324142C (en) 1993-11-09
EP0260305A1 (de) 1988-03-23
DE3783105T2 (de) 1993-04-22
ATE83376T1 (de) 1993-01-15
AU7162387A (en) 1987-10-09

Similar Documents

Publication Publication Date Title
DE3783105D1 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
DE3855501D1 (de) Chinolin-derivate als antagonisten von leukotrien d 4?
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
ATE383167T1 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69528604T2 (de) Medikamentenbehandlung erkrankter tiefliegender bereiche im inneren des körpers
DE3774918D1 (de) Cancerostatisches mittel.
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
ATE158183T1 (de) Arzneimittel zur behandlung von anxietas
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
ATE204021T1 (de) Klonierung, expression und charakterisierung einer neuen form der phosphatidylinositol-3- kinase
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE59107536D1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
NO162557C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive (pyrrol-1-yl)-fenyldihydropyridazinoner.
SE8704979D0 (sv) New furanuronic acid derivatives, process for their production and their use
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
FI844645L (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ATE82124T1 (de) Anwendung von n-(2-(diaethylamino)aethyl>-2-methoxy-4((1-h-4,5ihydro-2-imidazolyl)amino>-5- chlorobenzamid als anxiolytisches und antipsychotisches mittel.
DE59709081D1 (de) Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung und Prävention der Alzheimer'schen Krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee